Hunter Biden, former Vice President Joe Biden’s son, is still a board member of the Chinese private equity firm he promised to resign from in October, according to the Daily Caller News Foundation’s recent report.
Chinese business records reviewed by the DCNF Tuesday reveal that Hunter Biden maintains a director status with the company, BHR. Moreover, the news site found that Hunter Biden’s company, Skaneateles LLC, has a 10 percent equity stake in the firm.
From the Daily Caller:
“BHR manages the equivalent of $2.1 billion in assets, according to its website. Hunter Biden has served as an unpaid member of BHR’s board since its founding in 2013, and in October 2017 he obtained his equity stake in the firm with a $420,000 investment, according to Mesires.”
On Oct. 13, Hunter Biden issued his pledge to resign from BHR’s board “on or by October 31.” His father praised the move.
“The statement my son put out today, which I saw when he put it out — I was told it was going to be put out, I did not consult with him about what’s being put out — in fact represents the kind of man of integrity he is,” Joe Biden said in October of his pledge to resign.
Hunter Biden became a central figure in the impeachment probe into President Donald Trump over a now-debunked allegation that the President threatened to withhold aid to Ukraine in exchange for an investigation into Hunter’s paid board membership with a Ukrainian gas company, Burisma holdings, while his father was in charge of Ukraine affairs under the Obama administration. The President was acquitted in February.
You may like
Biden to lift sanctions on China in exchange for third promise to combat fentanyl
Reportedly President Joe Biden is making deals with Chinese President Xi Jinping to help improve anti-drug trafficking measures. China is one of the top fentanyl producers and distributors, culminating in a pandemic of fentanyl overdoses and deaths in the United States.
The Biden administration will be lifting sanctions on a Chinese government ministry, in exchange for bolstering anti-drug trafficking measures, Bloomberg reported. “We’re hoping to see some progress on that issue this coming week,” National Security Advisor Jake Sullivan said Monday, according to the New York Post. “That could then open the door to further cooperation on other issues where we aren’t just managing things, but we’re actually delivering tangible results.”
The Daily Caller News Foundation noted that should a deal materialize, it will be at least the third time that China has promised to get tough on fentanyl. In 2016, China agreed to increase counter-narcotics operations, and Xi again agreed to launch a crackdown in 2018. Nonetheless, China and Mexico are “the primary source countries for fentanyl and fentanyl-related substances trafficked directly into the United States,” according to a 2020 DEA intelligence report.
“China remains the primary source of fentanyl and fentanyl-related substances trafficked through international mail and express consignment operations environment, as well as the main source for all fentanyl-related substances trafficked into the United States.”
President Joe Biden and Xi are meeting for the first time in over a year during this week’s Asia Pacific Economic Cooperation (APEC) summit in San Francisco. Sources familiar with the situation told Bloomberg that the People’s Republic of China (PRC) will crack down on Chinese companies manufacturing chemical precursors for fentanyl in exchange for the U.S. lifting sanctions on the Ministry of Public Security’s Institute of Forensic Science, which the Commerce Department added to the Entity List in 2020 for “engaging in human rights violations and abuses” in the Xinjiang Uyghur Autonomous Region.
You may like
Media6 days ago
New family comedy ‘Jingle Smells’ executive produced by Sean Hannity releases a day early
Nation3 days ago
Group backed by the Islamic Republic of Iran hacked into PA Water Facility
Israel6 days ago
VIDEO: first hostages released by Hamas
Nation3 days ago
Elizabeth Warren Acknowledges Unintended Consequences of Obamacare